Introduction {#S0001}
============

Lung cancer is a major cause of cancer-related death. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers.[@CIT0001] Advanced NSCLC with activating mutations in the epidermal growth factor receptor (*EGFR*) gene is a distinct subtype of disease that is characterized by a high tumor response rate when treated with small molecule EGFR-tyrosine kinase inhibitors (TKIs). Meta-analyses have clearly shown improvements in progression-free survival (PFS) and response rates in patients with *EGFR* mutations who receive EGFR-TKI therapy, including gefitinib, erlotinib, and afatinib, as compared to those in patients who receive chemotherapy with cytotoxic drugs.[@CIT0002]--[@CIT0005] Based on these results, EGFR-TKI has become a standard regimen for patients with advanced NSCLC harboring *EGFR* mutation. Regarding the efficacy of EGFR-TKI, we previously reported the association between smoking status and efficacy of EGFR-TKI including gefitinib and erlotinib.[@CIT0006],[@CIT0007] Moreover, we reported the association between body size (BSA and BMI) of patients and efficacy of EGFR-TKIs.[@CIT0008] However, despite initial responses to EGFR-TKI therapy, the majority of patients will exhibit disease progression within 1--2 years due to acquired resistance.[@CIT0009]--[@CIT0017] In approximately 60% of patients, the mechanism of acquired resistance is the occurrence of an additional *EGFR* mutation, T790M.[@CIT0016]

Osimertinib is a mono-anilino-pyrimidine compound that irreversibly and selectively targets EGFR-TKI-sensitizing and T790M resistance-mutant forms of EGFR, while sparing wild-type EGFR.[@CIT0018]--[@CIT0020] A phase I/II AURA trial was conducted to reveal the safety and efficacy of osimertinib in patients with advanced NSCLC who experienced disease progression after previous treatment with EGFR-TKIs.[@CIT0021] Among the patients with a T790M mutation, osimertinib showed high efficacy, with an objective response rate (ORR) of 61% and a median PFS of 9.6 months. To further confirm the results of this, a randomized, phase III AURA (AURA III) trial was conducted that demonstrated the superiority of osimertinib treatment over standard chemotherapy with platinum plus pemetrexed in patients with *EGFR*-mutated and centrally confirmed T790M-positive advanced NSCLC with disease progression after first-line EGFR-TKI therapy.[@CIT0022] The results of the AURA III trial indicated a significantly longer PFS for patients receiving osimertinib than for those treated with platinum chemotherapy, establishing the role of osimertinib as a standard of care for patients who show disease progression after first-line EGFR-TKI and who harbor the T790M resistance mutation. However, the difference in efficacy of osimertinib among NSCLC patients according to their *EGFR* genotypes, such as whether they harbor the exon 19 deletion or L858R point mutation, remained unclear. Thus, the aim of this study was to determine whether the *EGFR* genotype affects the efficacy of osimertinib in patients with advanced NSCLC harboring the T790M mutation.

Patients and methods {#S0002}
====================

Patient selection {#S0002-S2001}
-----------------

We conducted a prospective observational cohort study at Kitasato University Hospital between January 2017 and December 2018 and evaluated the efficacy and safety of osimertinib in patients with T790M-positive advanced NSCLC who showed disease progression after first-line EGFR-TKI therapy, including gefitinib, erlotinib, and afatinib. The eligibility criteria of this study were as follows: histologically or cytologically confirmed NSCLC harboring both an EGFR major mutation and T790M, and stage IV disease or recurrence according to the new Union for International Cancer Control criteria, version 8. We excluded patients who did not have at least one measurable lesion according to the response evaluation criteria in solid tumors (RECIST) 1.1 criteria.[@CIT0001] Patient characteristics, including age at diagnosis, gender, Eastern Cooperative Oncology Group (ECOG) performance status (PS) at the start of osimertinib treatment, smoking status, clinical stage, tumor histology, brain metastasis status, number of metastatic lesions, and number of previous chemotherapy regimens, were identified by a chart review. The institutional ethics review board of the Kitasato University Hospital approved this study. This prospective observational study was conducted in accordance with the tenets of the declaration of Helsinki. All patients provided written informed consent before enrollment into this study. After obtaining written consent, the patients were treated with 80 mg of osimertinib daily until disease progression or unacceptable adverse events.

Analysis of EGFR mutations {#S0003}
==========================

A sample of the primary tumor, a metastatic lesion, or pleural effusion fluid was used as a specimen to test for *EGFR* mutations using the PNA-LNA PCR clamp method in the first evaluation of EGFR mutation status. Tumor re-biopsy specimens, along with plasma specimens recovered by liquid biopsy, were tested for *EGFR* T790M status using the Cobas EGFR Mutation Test (Roche, Basel, Switzerland).

Response assessment {#S0003-S2001}
-------------------

After initiation of osimertinib treatment, diagnostic imaging, ie, computed tomography (CT), of the chest and abdomen was carried out every 2--3 months or at more frequent intervals. PET or bone scintigraphy and CT or magnetic resonance imaging (MRI) of the cranium were carried out when patients had significant symptoms associated with tumor lesions or at 6-month intervals. Response to treatment was re-evaluated for this study by two investigators (S.I. and T.O.) according to the RECIST 1.1 criteria.[@CIT0001]

Statistical analysis {#S0003-S2002}
--------------------

PFS was measured from the start of osimertinib therapy to treatment failure (death, documentation of disease progression or appearance of unacceptable toxicity) or date of censoring at the last follow-up examination. Overall survival (OS) was defined as the interval between the start of osimertinib therapy and death from any cause or date of censoring. The survival curves were plotted using the Kaplan-Meier method, and differences according to the type of *EGFR* mutation were analyzed by the log-rank test. Variables including age, gender, smoking status, PS, stage, brain metastasis status, *EGFR* genotype, and number of prior regimens were used for fitting Cox's proportional hazard models to predict the hazard ratio for PFS and OS. Differences in the response rates according to the *EGFR* genotype were compared by Fisher\'s exact test. A *P-*value \<0.05 was used as the criterion for determining statistical significance. All statistical analyses were performed using the SPSS software program, version 17.0 (SPSS Inc., Chicago, IL, USA) for Windows.

Results {#S0004}
=======

Patient characteristics {#S0004-S2001}
-----------------------

A total of 51 NSCLC patients treated with osimertinib between May 2016 and October 2018 were included in the final analysis. The basic characteristics of the patients were as follows ([Table 1](#T0001){ref-type="table"}): 65% were female, the median age was 71 years, and 67% had a good PS (PS 0 or 1). All patients had adenocarcinoma (51 patients, 100%). The exon 19 deletion was found in 33 (65%) patients, and the L858R point mutation in 18 (35%). The results for the categorical variables showed that there were significantly higher percentages of females and non-elderly patients (\<75 years) in the exon 19 deletion group than in the L858R point mutation group ([Table 2](#T0002){ref-type="table"}).Table 1Patient characteristicsCharacteristicsn = 51 (%)Age (years), median, range71 (42--91)Gender Male/Female18 (35)/33 (65)Performance status 0--1/2--334 (67)/17 (33)*EGFR* genotype Del 19/L858R33 (65)/18 (35)Histology Adenocarcinoma51 (100)Stage IV/Recurrence42 (82)/9 (18)Smoking status Current smoker16 (31) Never or former light smoker35 (69)Type of prior EGFR-TKI\
Gefitinib/Erlotinib/Afatinib35 (69)/11 (22)/5 (10)Brain metastasis\
 Positive/Negative19 (37)/32 (63)Number of metastatic lesions 119 (37) ≥232 (63)Number of prior regimens (Median, range)2 (1--6) 123 (45) ≥228 (55)[^1] Table 2Patient characteristics according to *EGFR* genotypeCharacteristicsDel 19L858R*P*-valueGender Male12120.04 Female216Age (years) \<752570.01 ≥75811PS 0--123120.53 2--3106Smoking status Current smoker870.92 Never or former light smoker2511Stage Post-operative recurrence630.61 Stage IV2715Brain metastasis Positive1090.14 Negative239Prior regimens 11490.41 ≥2199[^2]

Response to osimertinib according to EGFR genotype {#S0005}
==================================================

[Table 3](#T0003){ref-type="table"} shows objective tumor responses. An objective response was obtained in 29 of the 51 patients, indicating an objective response rate (ORR) of 58.8% (95% confidence interval \[CI\]=42.3--75.3%). The response rate was 69.7% (95% CI=50.0--89.4%) in patients with exon 19 deletion and 38.9% (95% CI=18.0--59.7%) in patients with L858R mutation, indicating a statistically significant difference (*P*=0.033). Among patients showing a partial response, there was no significant difference in the median time to response between the two genotypes, with values of 1.8 months for the exon 19 deletion group and 1.4 months for the L858R point mutation group (*P*=0.61, [Figure 1](#F0001){ref-type="fig"}).Table 3Response rates according to *EGFR* genotypeAll patients\
(n=51)Del 19\
(n=33)L858R\
(n=18)Complete response000Partial response30237Stable disease1266Progressive disease835Not evaluable110Response rate58.8%69.7%38.9%*P*=0.033[^3] Figure 1Time to response to osimertinib therapy according to *EGFR* genotype.

Survival analysis {#S0005-S2001}
-----------------

The cut-off date for the survival data update was February 2019. The median follow-up period at the time of survival analysis was 11.3 months. The median PFS and OS of the entire patient population were 7.8 months (95% CI=6.7--8.9 months, [Figure 2A](#F0002){ref-type="fig"}) and 15.5 months (95% CI=10.0--21.0 months, [Figure 2B](#F0002){ref-type="fig"}), respectively. Median PFS in the exon 19 deletion group and L858R group was 8.0 months (95% CI=6.4--9.6 months) and 5.2 months (95% CI=3.5--6.9 months), respectively, indicating a statistically significant difference (*P*=0.045, [Figure 3A](#F0003){ref-type="fig"}). Median OS in the exon 19 deletion group and L858R group was 19.8 months (95% CI=13.0--26.6 months) and 12.9 months (95% CI=1.9--23.9 months), respectively, indicating a statistically significant difference (*P*\<0.0015, [Figure 3B](#F0003){ref-type="fig"}). The multivariate analysis identified *EGFR* genotype and number of prior regimens as independent predictors of PFS ([Table 4](#T0004){ref-type="table"}). Additionally, the multivariate analysis identified PS, *EGFR* genotype, brain metastasis, and stage as independent prognostic factors of OS ([Table 5](#T0005){ref-type="table"}).Table 4Multivariate analysis of prognostic factors for progression-free survivalUnivariate analysisMultivariate analysisVariableHazard ratio (95% CI)*P*-valueHazard ratio (95% CI)*P*-valueGender\
 Male vs Female0.91 (0.47--1.76)0.79Age (years), median, range\
 \<75 vs ≥750.71 (0.37--1.38)0.31Performance status\
 0--1 vs 2--31.66 (0.84--3.30)0.15Excluded*EGFR* genotype\
 Exon 19 deletion vs\
 L858R point mutation1.90 (1.06--3.74)0.0412.66 (1.28--5.54)0.009Smoking status\
 Current smoker vs\
 Never or former light smoker1.18 (0.59--2.34)0.64Stage\
 Postoperative recurrence vs\
 Stage IV1.80 (0.75--4.32)0.192.46 (0.99--6.18)0.052Brain metastasis\
 Positive vs Negative1.78 (0.94--3.36)0.078ExcludedNumber of prior regimens\
 0 vs ≥12.80 (1.39--5.68)0.0262.77 (1.37--5.60)0.004[^4] Table 5Multivariate analysis of prognostic factors for overall survivalUnivariate analysisMultivariate analysisVariableHazard ratio (95% CI)*P*-valueHazard ratio (95% CI)*P*-valueGender\
 Male vs Female0.98 (0.45--2,11)0.95Age (years), median, range\
 \<75 vs ≥751.64 (0.78--3.47)0.19ExcludedPerformance status\
 0--1 vs 2--33.53 (1.58--7.89)0.0024.72 (1.95--11.4)\<0.001*EGFR* genotype\
 Exon 19 deletion vs\
 L858R point mutation3.16 (1.50--6.69)0.0032.93 (1.32--6.50)0.008Smoking status\
 Current smoker vs\
 Never or former light smoker1.35 (0.61--2.98)0.46Stage\
 Post-operative recurrence vs\
 Stage IV2.79 (0.95--8.15)0.0623.46 (1.12--10.7)0.031Brain metastasis\
 Positive vs Negative3.89 (1.78--8.41)0.0014.11 (1.74--9.74)0.001Number of prior regimens\
 0 vs ≥11.95 (0.90--4.21)0.089Excluded[^5] Figure 2Kaplan-Meier plots of (**A**) PFS; and (**B**) OS for all patients.Figure 3Kaplan-Meier plots of (**A**) PFSand (**B**) OS according to *EGFR* genotype.

Discussion {#S0006}
==========

The advent of targeted therapy has revolutionized treatment for a subset of patients with NSCLC, and testing patients with newly-diagnosed NSCLC for the presence of an *EGFR* mutation is now considered the standard of care. However, in approximately 60% of patients, the mechanism of acquired resistance to first- or second-generation EGFR-TKIs is the occurrence of an additional *EGFR* mutation, T790M,[@CIT0023] and osimertinib is a key drug for the treatment of patients with acquired resistance by T790M mutation. The results of the present study showed that the response rate, PFS, and OS differed significantly according to *EGFR* genotype among patients with T790M-positive advanced NSCLC who had disease progression after first-line EGFR-TKI therapy. To our knowledge, this is the first report prospectively evaluating the relationship between the efficacy of osimertinib treatment and the *EGFR* genotype in NSCLC patients limited to the Asian population, and showing that the exon 19 deletion group had significantly better clinical outcomes including response rate, PFS, and OS compared with the L858R group.

OPTIMAL and ENSURE, phase III studies that evaluated erlotinib compared with platinum doublets, showed a trend toward improved PFS in patients with exon 19 deletions compared with that in patients with L858R point mutations.[@CIT0024],[@CIT0025] Another prospective study of 36 patients treated with either gefitinib or erlotinib observed improved OS among patients with exon 19 deletions as compared with that among patients with L858R point mutation, as well as trends toward higher response rates and improved PFS.[@CIT0026] Moreover, in a phase III trial comparing erlotinib with gefitinib in NSCLC patients with *EGFR* mutations,[@CIT0027] it was shown that patients with *EGFR* exon 19 deletions had a significantly higher response rate and longer median OS than those with L858R point mutations treated with erlotinib or gefitinib. A recent meta-analysis using randomized trial data from studies of patients receiving first-line treatment with first- and second-generation EGFR-TKIs revealed an impact of mutation subtype on PFS outcome.[@CIT0028] In the meta-analysis, a total of seven studies involving 1,649 patients treated with gefitinib, erlotinib, or afatinib were included, and the majority of patients harbored common *EGFR* mutations, including 872 patients with exon 19 deletion and 686 patients with L858R point mutations. Patients with exon 19 deletion showed a significantly greater PFS benefit when treated with an EGFR-TKI than did patients with L858R point mutation. Likewise, another meta-analysis reported that exon 19 deletion was associated with longer PFS compared to L858 mutation upon treatment with first- or second-generation EGFR-TKIs.[@CIT0029] Moreover, another study used kinetic analysis of these two mutations to show that tumors harboring exon 19 deletions appeared to be more sensitive to erlotinib inhibition than tumors harboring L858R.[@CIT0030] Importantly, Auriac et al[@CIT0031] reported a retrospective study, indicating that patients with exon 19 deletion showed a significantly longer PFS and OS when treated with osimertinib than did patients with L858R point mutation. Likewise, there was a trend toward an increased response rate in patients who had co-occurring EGFR T790M mutations and exon 19 deletions, vs that in patients with EGFR T790M mutations with L858R (70% vs 57%) in a pooled analysis of two previously reported phase 2 studies (AURA extension and AURA2)[@CIT0032] [Table 6](#T0006){ref-type="table"} summarizes the results of studies that compared the efficacy of osimertinib in terms of PFS and OS according to the *EGFR* mutation sub-type. Regarding the efficacy of osimertinib in patients with untreated *EGFR*-mutated NSCLC, FLAURA, a global phase III study[@CIT0033] showed that PFS of patients with exon 19 deletions and those with L858R were 21.4 months and 14.4 months, indicating a trend toward an increased PFS in the exon 19 deletion group compared with that in the L858R group. Therefore, the findings of our study support the results of these previous reports.Table 6Summary of studies comparing the efficacy of osimertinib for advanced NSCLC according to subtype of EGFR mutationResponse ratePFS (months)OS (months)nExon19L858R*P*Exon19L858R*P*Exon19L858R*P*Auliac et al[@CIT0031]185NANANA13.59.70.04923.115.30.03Ahn et al[@CIT0032]39570%57%NA11.19.5NA29.121.4NAPresent study5169.7%38.9%0.0338.05.20.04519.812.90.0015[^6]

Additionally, there has been a report that the IC~50~ of osimertinib seems to be lower in PC-9 cells harboring an exon 19 deletion than in tumor H3255 cells harboring L858R according to an in vitro analysis.[@CIT0018]

A previous study demonstrated that the tumor mutation burden (TMB) was lower in patients with *EGFR*-mutant NSCLC than in those with wild-type *EGFR*; however, the TMB in patients with a L858R point mutation was significantly higher than that in patients with an exon 19 deletion.[@CIT0034] In addition, the study showed that the clinical benefit of first- or second-generation EGFR-TKI therapy was significantly less in the high-TMB group than in the low-TMB group.[@CIT0034] Based on these findings, it is reasonable to hypothesize that EGFR-TKIs are more effective in NSCLC patients with exon 19 deletion than in those with L858R point mutation due to differences in TMB between the *EGFR* genotypes.

A previous phase III (AURA III) trial reported an ORR to osimertinib of 71% (95% CI=65--76) and a PFS of 10.1 months in patients with T790M-positive advanced NSCLC who had disease progression after failure of first-line EGFR-TKI therapy.[@CIT0022] The response rate and PFS in the AURA III study appear to be higher than those in our study. In the AURA III study, not only did all of the patients have good PS, but also 96% of the patients had received only one prior regimen. In contrast, in our study, the number of patients with poor PS was 17 (33%) and the median number of chemotherapy regimens prior to osimertinib therapy per patient was two, likely explaining the differences in ORR and PFS between the AURA III trial and our study.

Further investigation is needed to clarify the differences in the efficacy of osimertinib according to the *EGFR* genotype of NSCLC patients based on in vitro or in vivo pre-clinical data. There were several limitations to our study. First, the sample size and median follow-up time may not have been sufficient, and this study was performed at a single institution. Second, there was an imbalance in patient characteristics between patients harboring the exon 19 deletion and those harboring the L858R point mutation. Third, whereas evidence showing that osimertinib is mostly recommended for treatment of advanced NSCLC patients with *EGFR* mutation as a first-line chemotherapy was recently established,[@CIT0033] we did not evaluate the issue of osimertinib therapy in the first-line setting.

Conclusion {#S0007}
==========

In conclusion, we revealed that patients with an *EGFR* genotype of exon 19 deletion had better clinical outcomes among advanced NSCLC patients treated with osimertinib as second-line therapy after the failure of first-line EGFR-TKI therapy. The result of the present study provides important information, suggesting that investigators should consider the proportions of various types of sensitive *EGFR* mutations as a stratification factor in designing or reviewing clinical studies involving osimertinib.
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Key points {#S0008}
==========

Osimertinib response rates, PFS and OS were affected by the type of *EGFR* mutation. Multivariate analysis indicated that the number of prior regimens, stage, and *EGFR* mutation were independent predictors of PFS and OS.
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[^1]: **Abbreviations:** EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.

[^2]: **Abbreviations:** EGFR, epidermal growth factor receptor; PS, performance status.

[^3]: **Abbreviation:** EGFR, epidermal growth factor receptor.

[^4]: **Abbreviation:** EGFR, epidermal growth factor receptor.

[^5]: **Abbreviation:** EGFR, epidermal growth factor receptor.

[^6]: **Abbreviations:** NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor; Exon 19, exon 19 deletion; NA, not available; OS, overall survival; *P, P*-value; PFS, progression-free survival.
